Exciting Offers Await at the 2024 Hong Kong Brands and Products Expo: Herbalgy Presents Exclusive Deals & Debuting “Yick Kee Balanced Tea Limited” Health Tea Bags!
Exclusive Discounts Up to 38% and Limited Edition Gifts HONG KONG, Dec. 4, 2024 /PRNewswire/ -- As December approaches, the highly anticipated Hong Kong Brands and Products Expo is just around the corner. Herbalgy Pharmaceutical Limited, a proud participant in this annual shopping event for many years, is excited to announce a...
LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System
Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring Web-based system displays multiple patient physiological data continuously, with visual alarms and alert notifications for streamlined patient care Developed to support...
“Closing the Women’s Health Gap – Highlights of Biotropics Malaysia clinical study by Women, on Women, for Women”
SHAH ALAM, Malaysia, Dec. 30, 2024 /PRNewswire/ -- While gender parity has seen progress in recent years, the women's health gap remains significant. Women, despite comprising half of the global labor force, often face under-diagnosis and under-representation in healthcare research. Biotropics Malaysia is addressing this disparity by advancing clinical studies led by women, focused on health areas that have been...
Datasea Pre-Announces Second Quarter Revenue of $20.5 Million, up 81% Year-over-Year
Gross Profit achieved a 310% Increase Year-over-Year BEIJING, Feb. 5, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), a Nevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced that its revenue for the second quarter of fiscal year 2025, ended December 31,...
BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS
"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA Editing Exploration of Nature at Shortest Distances Proof of Geometric Langlands Conjecture Special Prize Awarded to Giant of Theoretical Physics Breakthrough Prize in Life Sciences Awarded to Daniel J. Drucker, Joel Habener,...
QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines
SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel...
Arbele Wins Top Prize at BCIC’s 4th Annual Biomedical Pitch Competition
BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. and Asia, Arbele stood out for its groundbreaking research in CDH17-targeted immunotherapy and antibody-drug conjugates (ADCs). Arbele is developing novel treatments...
Bridge Capture™ enables sensitive, scalable liquid biopsy in colorectal cancer pilot
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 /PRNewswire/ -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports,...
Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease
The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation. Energenesis plans to advance ENERGI-F705PD into a Phase II trial....
Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation
Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally SEATTLE, Aug. 4, 2025 /PRNewswire/ -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded...
